Research library / Omega-3

AA Multiple randomized trials or meta-analyses, consistent results. How we grade →Science advisory · Review of prescription omega-3 trials

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

A Skulas-Ray, P Wilson, W Harris, E Brinton, P Kris-Etherton, C Richter et al. Circulation. 2019.

Published Sources checked 1 sourceEverstack research teamHow we work

Bottom line: An AHA advisory finds prescription omega-3s at 4 g per day lower triglycerides in adults with elevated triglycerides; it does not address lower-dose supplements in healthy adults.

In plain language
This American Heart Association science advisory summarizes the lipid effects of prescription omega-3 doses above 3 g per day of EPA plus DHA. In people with very high triglycerides (500 mg/dL or more), 4 g per day of EPA plus DHA lowered triglycerides by 30% or more but raised LDL cholesterol, while EPA alone did not raise LDL cholesterol. In people with triglycerides of 200 to 499 mg/dL, EPA plus DHA and EPA alone appeared roughly comparable for lowering triglycerides and did not raise LDL cholesterol, alone or with a statin. The advisory cites a 25% reduction in major cardiovascular events in REDUCE-IT, a trial of EPA alone in high-risk patients on statins.
Limits
About prescription doses (more than 3 g a day of EPA plus DHA) in people with high triglycerides, not supplements in healthy adults. It summarizes existing trials rather than new data, and the cardiovascular evidence rests mainly on one EPA-only trial in high-risk statin users, with an EPA plus DHA outcome trial still pending at the time.
Which of our grades it feeds
Source
doi.org/10.1161/CIR.0000000000000709 · PubMed 31422671

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. Reviewed . We sell some of what we grade.